Taltz (ixekizumab) is a monoclonal antibody known as an interleukin antagonist. It's used to treat inflammatory problems, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Taltz (ixekizumab) is available as a prefilled syringe and prefilled autoinjector. It's given as an injection under the skin once per month. Side effects include upper respiratory infections and injection-site reactions (e.g., pain, redness).
Moderate-to-severe plaque psoriasis in people ages 6 years and older
Psoriatic arthritis (PsA) in adults
Ankylosing spondylitis (AS) in adults
Non-radiographic axial spondyloarthritis (nr-axSpA) in adults
Taltz (ixekizumab) is a monoclonal antibody that works as an interleukin antagonist. It attaches to certain proteins in your immune system called interleukin-17 (IL-17) that play a role in causing inflammation. By attaching to IL-17, the medication blocks the proteins from working, which helps lower inflammation.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Given once per month (after the first few doses)
Available as a prefilled syringe or autoinjector for easier use
Can inject at home after proper training
Only given as an injection under the skin
Raises the risk of infections
Might cause flare ups in people with Crohn's disease or ulcerative colitis
Tell your provider or pharmacist that you're taking Taltz (ixekizumab) before you get any vaccines. Most vaccines are okay to get while you're taking this medication, but others, like live vaccines, might not be. Your providers can make sure you can get the vaccine you want.
Store Taltz (ixekizumab) in the carton it came in to protect it from light and place it in the refrigerator; be careful not to freeze the medication. You can also keep it at room temperature for up to 5 days; make sure to write down the new expiration date if you do.
If you miss a dose of Taltz (ixekizumab), take the medication as soon as possible. Then, continue with your usual dosing schedule.
Talk to your provider if you're pregnant or thinking of becoming pregnant. It's not known how safe Taltz (ixekizumab) is during pregnancy. If you're pregnant and you're taking this medication, it's recommended that you call 1-800-284-1695 to enroll in a registry that monitors you and your baby during treatment.
Don't breastfeed while you're taking Taltz (ixekizumab) unless your provider says it's safe to do so. There's not a lot of information about whether this medication is safe for you or your baby if you breastfeed.
Tips for injecting [Taltz (ixekizumab) under the skin at home:
Make sure you know how to properly and safely inject Taltz (ixekizumab) to avoid accidentally hurting yourself or wasting the medication. Carefully read the directions for using the autoinjector or prefilled syringe (whichever one you have). Ask your provider or pharmacist if you have any questions on how to use this medication.
When you're ready for your dose, take the Taltz (ixekizumab) syringe or autoinjector out of the carton and lay it on a flat surface to warm up. This should take about 30 minutes. Don't try to warm up the medication any other way (e.g., microwave, under hot water) because this can damage it. Don't shake the medication either.
Before you inject, always check that the medication inside is clear and colorless to slightly yellow. Don't use it if it's cloudy or discolored or if it has particles in it. Call your provider or pharmacist about a replacement.
Inject Taltz (ixekizumab) under the skin into your thighs or stomach (at least 1 inch away from your belly button). You can also ask someone to help inject the medication into the back of your arms.
Be sure to rotate injection sites for every injection. Don't inject into any area that's red, bruised, scaly, tender, or scarred or has stretch marks.
For the autoinjector: Remove the cap and hold the autoinjector flat against your skin at the injection site. Then, unlock your device and press the green injection button. You'll hear a click when your injection starts; make sure you hold the device in place until you hear a second click. The second click usually takes about 10 seconds and means that your injection is complete.
For the prefilled syringe: Remove the cap off the needle. Gently pinch and hold a fold of skin at the injection site, and insert the needle at a 45-degree angle. Let go of your skin, and slowly push the plunger on the syringe down to inject the medication. You should see the green plunger rod show up inside the syringe when the injection is complete.
After your injection, place the used autoinjector or prefilled syringe in a sharps container or a heavy-duty plastic container (e.g., empty milk carton, laundry detergent bottle). This lowers the risk for needle-stick injuries. Don't throw them away into your trash can. Visit the FDA's website for guidance on how to safely throw away your sharps container in your specific state.
Taltz (ixekizumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: Active, chronic, or recurrent infection | Having other conditions that raise your risk of infection
Taltz (ixekizumab) can affect your body's ability to fight off germs and raise your risk for bacterial, viral, or fungal infections. In clinical studies, people most commonly reported upper respiratory infections and fungal infections.
Taltz (ixekizumab) might also cause tuberculosis (TB). This can be either a new TB infection or an old one that's come back. Because of this risk, you'll need to get tested for TB before you start this medication and get treated if it's confirmed that you have TB. Tell your provider about your medical conditions and medications to make sure Taltz (ixekizumab) is safe to take.
Contact your provider if you develop symptoms of an infection, such as fever; cough; trouble breathing; diarrhea; weakness; night sweats; chills; or itchy, scaly, or burning skin. Your provider can examine you to see whether you have an infection. If you do, you might have to stop taking Taltz (ixekizumab) so your body can fight the infection.
Tell your provider or pharmacist that you're taking Taltz (ixekizumab) before you get any vaccines. You should avoid getting live vaccines while you're taking Taltz (ixekizumab). It's not known whether these types of vaccines are safe to get during treatment. Examples of live vaccines include Varivax (chickenpox vaccine) and MMR (measles, mumps, and rubella vaccine). It's best to be up to date on all your vaccines before you start Taltz (ixekizumab).
It's possible to have a serious allergic reaction to Taltz (ixekizumab). These allergic reactions can include trouble breathing; hives; swelling of your face, lips, tongue, or throat; or any other symptom of anaphylaxis. Get medical help right away if you have an allergic reaction to Taltz (ixekizumab) at any time during treatment.
People treated with Taltz (ixekizumab) might be at higher risk for inflammatory bowel disease (IBD). In clinical studies, some people who took Taltz (ixekizumab) had new or worsening IBD (i.e., flare-ups). Before you start this medication, let your provider know if you have a history of IBD. Contact your provider if you have stomach pain, bloody stools, diarrhea or constipation that doesn't get better, or sudden weight loss while you're taking Taltz (ixekizumab). These might be signs of IBD.
Taltz (ixekizumab) is given as an injection under the skin in the stomach, thighs, or back of the upper arms.
Plaque psoriasis
Age 18 years and older: The typical starting dose is 160 mg as a single dose, then 80 mg every 2 weeks for 12 weeks. After that, the typical maintenance dose is 80 mg every 4 weeks.
Age 6 to under 18 years: The dose is based on your child's weight.
Weight of greater than 110 lbs: The typical dose is 160 mg as a single dose, then 80 mg every 4 weeks.
Weight of 55 to 110 lbs: The typical dose is 80 mg as a single dose, then 40 mg every 4 weeks.
Weight of less than 55 lbs: The typical dose is 40 mg as a single dose, then 20 mg every 4 weeks.
Psoriatic arthritis or ankylosing spondylitis
Age 18 years and older: The typical dose is 160 mg as a single dose, then 80 mg every 4 weeks.
Non-radiographic axial spondyloarthritis
Age 18 years and older: The typical dose is 80 mg every 4 weeks.
Moderate-to-severe plaque psoriasis in people ages 6 years and older
Psoriatic arthritis (PsA) in adults
Ankylosing spondylitis (AS) in adults
Non-radiographic axial spondyloarthritis (nr-axSpA) in adults
Moderate-to-severe plaque psoriasis, in people who might benefit from systemic therapy (e.g., pills or injections) or treatment using ultraviolet (UV) light
Active psoriatic arthritis
Plaque psoriasis (PsO) in people ages 6 years and older
Psoriatic arthritis (PsA) in people ages 2 years and older who weigh at least 33 lbs
Ankylosing spondylitis (AS) in adults
Non-radiographic axial spondyloarthritis (nr-axSpA) in adults
Enthesitis-related arthritis in people ages 4 years and older who weigh at least 33 lbs
Hidradenitis suppurativa in adults
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Berman, J., et al. (2021). Treatment with ixekizumab following secukinumab failure in patients with psoriatic arthritis: Real-life experience from a resistant population. Biologics: Targets & Therapy.
Deodhar, A. (2019). What is non-radiographic axial spondyloarthritis? Spondylitis Association of America.
Drugs and Lactation Database (LactMed®). (2023). Ixekizumab. National Institute of Child Health and Human Development.
Eli Lilly and Company. (2021). Instructions for use: How to use the Taltz prefilled syringe.
Eli Lilly and Company. (2023). Instructions for use: Taltz® [tol-t-s] (ixekizumab) injection for subcutaneous use - Autoinjector.
Eli Lilly and Company. (2024). Taltz- ixekizumab injection, solution [package insert]. DailyMed.
Gordon, K. B., et al. (2016). Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. The New England Journal of Medicine.
Herrera-Acosta, E., et al. (2020). Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice. Dermatologic Therapy.
Nemours KidsHealth. (2021). Enthesitis-related juvenile arthritis.
Paller, A. S., et al. (2020). Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). The British Journal of Dermatology.
St Clair-Jones, A., et al. (2020). Understanding and minimising injection-site pain following subcutaneous administration of biologics: A narrative review. Rheumatology and Therapy.
U.S. Food and Drug Administration. (2021). Safely using sharps (needles and syringes) at home, at work and on travel.
van der Heijde, D., et al. (2018). Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1). The Journal of Rheumatology.
Zenobia, C., et al. (2015). Basic biology and role of interleukin-17 in immunity and inflammation. Periodontology 2000.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.